T Cell News and Research

Latest T Cell News and Research

Ground-breaking study into causes of high blood pressure

A researcher from the University of Leicester's Department of Cardiovascular Sciences has been involved in a ground-breaking study into the causes of high blood pressure.

9 Nov 2011

Study: Children with autism have more prefrontal brain neurons

In a small, preliminary study that included 13 male children, those with autism had an average 67 percent more prefrontal brain neurons and larger than average brain weight, than children without autism, according to a study in the Nov. 9 issue of JAMA.

9 Nov 2011

Protein p97/VCP aids DNA repair like a corkscrew

Human genetic material is constantly at risk of injury from the environment. Possible causes of damage include metabolic processes, chemical substances or ionizing radiation, such as X-radiation.

9 Nov 2011

Johns Hopkins researchers unravel how breast cancer metastasizes

The spread of breast cancer is responsible for more than 90 percent of breast cancer deaths. Now, the process by which it spreads—or metastasizes—has been unraveled by researchers at Johns Hopkins. Reporting in two papers, the researchers have discovered the switch that enables breast cancer cells to travel to and be received in the lungs.

9 Nov 2011

Tufts University professor earns March of Dimes Foundation award for tissue development

A new approach to studying tissue development has earned Catherine K. Kuo, Ph.D., an assistant professor of biomedical engineering in Tufts University's School of Engineering, the Basil O'Connor Starter Scholar Award from the March of Dimes Foundation.

9 Nov 2011

Another tool to fight pharmacy crime through Twitter

...

9 Nov 2011

Infinity third quarter total revenue increases marginally to $23.3 million

Infinity Pharmaceuticals, Inc. today highlighted its recent clinical and business progress and announced its third quarter 2011 financial results.

9 Nov 2011

BioTime third quarter revenue increases 40% to $1.1 million

BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and nine months ended September 30, 2011 and highlighted recent corporate accomplishments.

9 Nov 2011

CytRx reports net loss of $0.6 million for third quarter 2011

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and nine months ended September 30, 2011, and provided a business update.

9 Nov 2011

Interim data from Cytheris CYT107 Phase I/IIa combination study on HCV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.

9 Nov 2011

FDA accepts Genentech's vismodegib NDA for review

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

9 Nov 2011

Access partners to exploit CobaCyte and CobOral technology for targeted RNAi therapeutic delivery

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major player in RNAi industry to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.

9 Nov 2011

Omeros third quarter net loss decreases to $6.5 million

Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the third quarter of 2011.

9 Nov 2011

Second molecular conductor discovered in some children with biliary atresia

Unexpected discovery of a new molecular signature for a destructive and often lethal pediatric liver disease may lead to a new therapeutic target for the hard-to-treat condition.

9 Nov 2011

Prenatal processes gone awry linked to children with autism

A study by researchers at the University of California, San Diego Autism Center of Excellence shows that brain overgrowth in boys with autism involves an abnormal, excess number of neurons in areas of the brain associated with social, communication and cognitive development.

9 Nov 2011

University of Houston to enhance cancer research facilities

Thanks to almost $1 million in new funding from the Cancer Prevention and Research Institute of Texas (CPRIT), the University of Houston (UH) will soon be enhancing its cancer research facilities.

9 Nov 2011

Micromet's blinatumomab data to be reported at 53rd ASH annual meeting

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab (MT103) will be reported at the 53rd Annual American Society of Hematology (ASH) Annual Meeting, to be held December 10 - 13 in San Diego, California.

9 Nov 2011

Fluidigm third quarter total revenue increases 25% to $10.6 million

Fluidigm Corporation today announced its financial results for the third quarter ended September 30, 2011.

9 Nov 2011

ScreenCell, Transgenomic sign collaboration and distribution agreement for CTC technology

Transgenomic, Inc. and ScreenCell, a privately-held company, today announced the signing of a perpetual, worldwide collaboration and distribution agreement for ScreenCell's Isolation Devices and Dilution Buffers, designed for the collection of Circulating Tumor Cells (CTCs) in peripheral blood.

9 Nov 2011

Lapatinib drug could also treat head and neck cancers

A class of drugs used to treat breast cancers which overproduce a protein called HER2 could also treat other types of cancer - particularly head and neck cancers, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool this week.

8 Nov 2011